Get the Stockscreener App
1.69
2.31%
-0.04
After Hours:
1.67
-0.02
-1.18%
Heron Therapeutics Inc stock is traded at $1.69, with a volume of 1.02M.
It is down -2.31% in the last 24 hours and down -22.12% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.73
Open:
$1.73
24h Volume:
1.02M
Relative Volume:
0.68
Market Cap:
$257.83M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-10.56
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
-11.52%
1M Performance:
-22.12%
6M Performance:
-0.59%
1Y Performance:
-39.86%
1-Day Range:
$1.655
$1.735
1-Week Range:
$1.655
$1.93
52-Week Range:
$1.04
$2.88
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.69 | 263.94M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Monaco Asset Management SAM Sells 252,743 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
How volatile is Heron Therapeutics Inc. stock compared to the marketBreakout Stocks Tips For Beginners - jammulinksnews.com
Does Heron Therapeutics Inc. stock perform well during market downturnsTop Growth Ideas To Watch Now - jammulinksnews.com
When is Heron Therapeutics Inc. stock expected to show significant growthMarket Forecast Planner To Watch Now - jammulinksnews.com
Heron Therapeutics (HRTX) Expected to Announce Earnings on Monday - MarketBeat
Published on: 2025-07-29 22:59:39 - metal.it
Heron Therapeutics Announces Q2 2025 Earnings Call for August 11, 2025 - AInvest
How does Heron Therapeutics Inc. generate profit in a changing economyMarket Forecast Report For Fast Growth - jammulinksnews.com
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 - Yahoo Finance
Biotech Leader Heron Therapeutics Sets Q2 Earnings Call: Key Financial Results Coming August 11 - Stock Titan
What are the technical indicators suggesting about Heron Therapeutics Inc.Unlock powerful trading signals and alerts - jammulinksnews.com
New Product Launches: Will They Boost Heron Therapeutics Inc. Stock in 2025Free Real Time Alerts Based on AI Prediction - Newser
Why is Heron Therapeutics Inc. stock attracting strong analyst attentionMaximize gains with professional stock picks - jammulinksnews.com
How does Heron Therapeutics Inc. compare to its industry peersFree Predictions - jammulinksnews.com
What is Heron Therapeutics Inc. company’s growth strategyFree Stock Market Forecast Reports - jammulinksnews.com
Published on: 2025-07-27 20:33:02 - jammulinksnews.com
What makes Heron Therapeutics Inc. stock price move sharplyShort Term Profit Focus - Newser
AIGH Capital Management LLC Purchases Shares of 2,778,200 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
What institutions are buying Heron Therapeutics Inc. stock nowConsistently superior profits - jammulinksnews.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Holdings Raised by New York State Common Retirement Fund - MarketBeat
Is Heron Therapeutics Inc. stock a growth or value playConsistently superior profits - jammulinksnews.com
Is Heron Therapeutics Inc. a good long term investmentOutstanding investment returns - PrintWeekIndia
How Heron Therapeutics Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
Heron Therapeutics Inc. Stock Analysis and ForecastFree Buy/Sell Signal Notifications - Autocar Professional
What analysts say about Heron Therapeutics Inc. stockFree Stock Selection - Autocar Professional
What drives Heron Therapeutics Inc. stock pricePowerful profit generation - jammulinksnews.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by New York State Common Retirement Fund - Defense World
HRTX SEC FilingsHeron Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is Heron Therapeutics Inc. stock a good hedge against inflationPotential Rocket List - Newser
Heron Therapeutics: Middling Performance From Approved Therapies With No Pipeline - Seeking Alpha
When Will Heron Therapeutics, Inc. (NASDAQ:HRTX) Breakeven? - simplywall.st
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):